CervoMed (NASDAQ:CRVO) is scheduled to announce Q2 earnings results on Monday, July 28th, before market open. The consensus EPS Estimate is -$0.62 (-129.6% Y/Y) and the consensus Revenue Estimate is ...

Key Points - Diluted earnings per share (GAAP) were $0.82, surpassing estimates for Q2 2025, beating consensus by $0.03. Revenue (GAAP) decreased to $38.0 million for the three months ended June 30, ...

Non-performing assets increased to 0.72% of total assets in Q2 2025, driven by a rise in a single commercial & industrial non-accrual loan. These 10 stocks could mint the next wave of millionaires › ...

Key Points - GAAP EPS of $0.24 topped analyst estimates by 4.4% in Q2 2025, with GAAP revenue beating estimates by 6.5% in Q2 2025 - Net interest margin expanded to 2.57%, up from 2.09% a year earlier ...

Intel Corporation, NVIDIA Corporation, ASML Holding NV, Advanced Micro Devices Inc. Read 's Market Analysis on Investing.com ...

The automotive parts supplier reduced its 2025 outlook, as it continues to execute its plan to cut $200 million in costs over ...

VeriSign (NASDAQ:VRSN) was trading higher despite mixed second-quarter results as the internet infrastructure and domain name ...

Key Points Revenue rose 13% to $1.94 billion in Q2 2025, surpassing analyst estimates for non-GAAP EPS and driven by both organic growth (+7%) and acquisitions (+6%). Adjusted EPS came in at $4.87, ...

The quarterly dividend remained steady at $0.15 per share as share buybacks contributed to book value growth. These 10 stocks could mint the next wave of millionaires › Waterstone Financial ...

Key Points - Earnings per share (GAAP) rose to $0.20 in Q2 2025, beating the analyst estimate by $0.01. Net interest margin improved to 2.52%, with gains from higher prepayment fees and deposit cost ...

Teradyne Inc. (NASDAQ: TER) is one of the most oversold semiconductor stocks so far in 2025. On July 21, UBS analyst Timothy Arcuri raised the price target on Teradyne (NASDAQ:TER) to $120 from $110, ...

Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...